Zimmer Biomet Valuation After a Year of Weak Share Price Performance: Undervalued with Upside Potential

Zimmer Biomet Holdings (ZBH) has seen its share price decline 10% over the past three months and 14% over the past year, despite steady revenue and earnings growth. The company's investment in digital health, robotics, and data-driven surgical solutions is driving margin expansion and recurring revenues, supporting higher net margins and earnings predictability. However, pricing pressure and intensified robotic competition could cap margins and dilute the long-term growth story.